valsartan has been researched along with ST Elevated Myocardial Infarction in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Deng, Q; Diao, K; He, S; He, Y; Huang, B; Li, C; Ma, M; Sun, J; Tang, L; Wang, D; Wang, H; Wang, M; Wu, T; Wu, X; Yan, T; Zhang, L; Zhu, Y | 1 |
| Chen, W; Dai, C; Lin, G; Wu, M; Xu, K | 1 |
| Barbato, E; Bellis, A; Di Gioia, G; Mauro, C; Morisco, C; Sorriento, D; Trimarco, B | 1 |
| El Nozahi, M; Rezq, A; Saad, M | 1 |
| Bae, WH; Hong, TJ; Hur, SH; Hwang, JY; Jeong, B; Kim, BS; Kim, KS; Kim, YD; Lee, SG; Lee, SH; Oh, JH; Park, JS; Park, K; Park, TH; Yang, TH | 1 |
1 review(s) available for valsartan and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction.
Topics: Adrenomedullin; Aminobutyrates; Angiotensin II; Animals; Apelin; Atrial Natriuretic Factor; Biphenyl Compounds; Bradykinin; Cardiotonic Agents; Drug Combinations; Gene Expression Regulation; Humans; Mice; Myocardial Reperfusion Injury; Neprilysin; ST Elevation Myocardial Infarction; Substance P; Survival Analysis; Tetrazoles; Valsartan; Ventricular Remodeling | 2020 |
4 trial(s) available for valsartan and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Prospective Studies; ST Elevation Myocardial Infarction; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Remodeling | 2021 |
The Value of Sacubitril/Valsartan in Acute Anterior Wall ST-Segment Elevation Myocardial Infarction before Emergency Percutaneous Coronary Intervention.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
Topics: Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Diseases; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Ramipril; ST Elevation Myocardial Infarction; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
The impact of a dose of the angiotensin receptor blocker valsartan on post-myocardial infarction ventricular remodelling.
Topics: Angiotensin II Type 1 Receptor Blockers; Dose-Response Relationship, Drug; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Male; Middle Aged; Retrospective Studies; Single-Blind Method; ST Elevation Myocardial Infarction; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2018 |